Market Cap (In USD)
11.14 Thousand
Revenue (In USD)
49.72 Million
Net Income (In USD)
-51.69 Million
Avg. Volume
47.00
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 1.0E-6-0.006
- PE
- -
- EPS
- -
- Beta Value
- 27.759
- ISIN
- IE00BF2HDL56
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Brian A. Markison
- Employee Count
- -
- Website
- https://www.rvlpharma.com
- Ipo Date
- 2018-10-18
- Details
- RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. It is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022. RVL Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.
More Stocks
-
CEM
-
1U11&1 AG
1U1
-
ENVIPEnvipco Holding N.V.
ENVIP
-
6809TOA Corporation
6809
-
3023Rasa Corporation
3023
-
3301
-
SHBI
-
USM